Avacta Group plc, a life sciences company specializing in targeted cancer treatments and diagnostics, has announced the successful passing of all resolutions, except for Resolution 6, at its Annual General Meeting. The full text of each resolution is available on the company's website, along with presentation materials, including slide decks and a video presentation by CEO Christina Coughlin. Shareholders can access these materials on the Investor Resources section of the company's website.
Avacta Group plc, with a focus on improving healthcare outcomes, operates through two divisions: Avacta Therapeutics, a clinical stage oncology biotech division, and Avacta Diagnostics, which supports healthcare professionals and broadens access to diagnostics. The company utilizes two proprietary platforms, pre|CISION™ and Affimer®, to develop novel, highly targeted cancer drugs. The pre|CISION™ platform specifically targets fibroblast activation protein (FAP), which is upregulated in most solid tumors compared with healthy tissues, allowing for optimized dosing to deliver the best outcomes for patients.
For further information, individuals can contact Avacta Group plc directly or visit their website.